The present invention pertains generally to immunomodulation by altering levels of the proinflammatory chemokines. In particular, the invention relates to methods of modulating an immune response with UMLiLo, a long non-coding RNA that regulates expression of the ELR+ proinflammatory chemokines. The invention further relates to methods of treating inflammatory, autoimmune, and infectious diseases, immunodeficiency, and cancer by reducing levels of chemokines.
Novel mechanisms for immunomodulation by altering levels of the proinflammatory chemokines and for using same approach treating diseases that have an inflammatory related physiology
